Aktuellt
SENASTE
Redeye leaves an initial comment following the Q3 report published by Magle this morning. During the third quarter of 2024, Magle completed the merger with pK Biotech (pK Chemicals) and is closing the merger with Amniotics. As previously explained, we are encouraged by the company’s M&A activity and believe that both of these are poised to generate long-term shareholder value for Magle. This is evident in the financials of the company’s Q3 report, as the company reported significantly higher sales figures and EBIT than previous quarters.
LÄS MER
